Cumulus Neuroscience published results from its CNS-102 study in Scientific Reports, showing its at-home NeuLogiq platform can be used for people living with ALS and frontotemporal dementia. Over an eight-month protocol, the platform combined a wireless EEG headset with tablet-based cognitive tasks, with 82% of ALS participants rating it easy to use despite significant motor and cognitive impairment. The study is the first to combine at-home EEG and multi-domain cognitive assessment in this population.

Cumulus Neuroscience published results from its CNS-101 study in Frontiers in Digital Health, reporting that its NeuLogiq platform was feasible, well tolerated, and usable for at-home cognitive and EEG assessment in people with mild Alzheimer's disease. The 52-week study, designed with ten pharmaceutical companies and run with the University of Cambridge, combines a wireless EEG headset with tablet-based cognitive tasks to capture frequent, longitudinal data outside the clinic.